永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

复活节星期一翌日休市 04-02 16:08:19

2.720

-0.020

-0.73%

最高2.740	最低2.660	成交量11.00万
今开2.740	昨收2.740	日振幅2.92%
总市值16.81亿	流通市值16.81亿	总股本6.18亿
成交额29.52万	换手率0.02%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":2.72,"timestamp":1775117299732,"preClose":2.74,"halted":0,"volume":110010,"delay":0,"changeRate":-0.0072992700729927066,"floatShares":618000000,"shares":618000000,"eps":-0.4787101375445747,"marketStatus":"复活节星期一翌日休市","change":-0.02,"latestTime":"04-02 16:08:19","open":2.74,"high":2.74,"low":2.66,"amount":295196,"amplitude":0.029197,"askPrice":2.72,"askSize":4000,"bidPrice":2.64,"bidSize":3000,"shortable":0,"etf":0,"ttmEps":-0.47187142129393794,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775611800000},"marketStatusCode":7,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":2.74,"openAndCloseTimeList":[[1775093400000,1775102400000],[1775106000000,1775116800000]],"volumeRatio":0.4876718888442354,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2625676541","title":"2025年中国创新药上市公司收入突破1000亿元 我们离全球“领跑”还有多远？","url":"https://stock-news.laohu8.com/highlight/detail?id=2625676541","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625676541?lang=zh_cn&edition=full","pubTime":"2026-04-06 19:02","pubTimestamp":1775473345,"startTime":"0","endTime":"0","summary":"随着2025年各家上市公司年报密集出炉，中国创新药产业的结构性变革正式浮出水面。据《每日经济新闻》记者（以下简称每经记者）不完全统计，百济神州、信达生物、华领医药、诺诚健华、乐普生物、荣昌生物、迈博药业、北海康成等公司扭亏为盈。创新药企终于从“烧钱”走向“赚钱”。与此同时，中国已跃升为全球创新药优质在研管线的核心供给地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604063695802194.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604063695802194.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","BK1161","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625549620","title":"广生堂最新公告：乙肝创新药尚处于在研阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2625549620","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625549620?lang=zh_cn&edition=full","pubTime":"2026-04-06 15:39","pubTimestamp":1775461170,"startTime":"0","endTime":"0","summary":"广生堂(300436.SZ)公告称，公司股票自2026年4月1日至4月3日连续三个交易日收盘价格涨幅偏离值累计超过30%，属于股票交易异常波动。公司乙肝创新药尚处于在研阶段。创新药研发周期长，投入大，风险高，容易受到多方面因素的影响，临床研究存在结果不及预期甚至失败的风险，后续能否获得批准上市存在不确定性，短期内对公司业绩不会产生重大影响。敬请广大投资者谨慎决策，注意防范投资风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040600001655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159992","06978","BK1574","300436","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625923649","title":"1月翻倍！又有创新药妖股诞生","url":"https://stock-news.laohu8.com/highlight/detail?id=2625923649","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625923649?lang=zh_cn&edition=full","pubTime":"2026-04-05 17:45","pubTimestamp":1775382327,"startTime":"0","endTime":"0","summary":"3月创新药妖股频出，意味着什么信号?","market":"us","thumbnail":"https://img3.gelonghui.com/6f3f2-0470ab12-a8ce-4d28-b30d-2aaf0d2afce5.jpg?guru_height=717&guru_width=1280&guru_size=209034","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/6f3f2-0470ab12-a8ce-4d28-b30d-2aaf0d2afce5.jpg?guru_height=717&guru_width=1280&guru_size=209034"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4310631","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["002082","159992","06978","BK0028","BK0239","BK0050","BK1574","BK1161","BK0004"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625964824","title":"强势反弹！创新药业绩盈利周期开启，BD出海狂飙突进","url":"https://stock-news.laohu8.com/highlight/detail?id=2625964824","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625964824?lang=zh_cn&edition=full","pubTime":"2026-04-05 11:38","pubTimestamp":1775360280,"startTime":"0","endTime":"0","summary":"经历了将近半年的大幅调整，创新药指数近期明显反弹。Wind创新药概念指数在过去1个月上涨了8.47%，同期沪深300指数下跌了4.62%。机构分析指出，创新药板块当前具备宏观资金面与产业基本面的双重支撑：一方面，美债收益率与A股创新药行情呈现显著的负相关关系，美债收益率拐点往往亦是创新药行情的拐点；另一方面，创新药出海持续放量，基本面韧性强劲。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604053695665449.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","06978","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624695134","title":"突然杀回来了！创新药ETF大盘点！","url":"https://stock-news.laohu8.com/highlight/detail?id=2624695134","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624695134?lang=zh_cn&edition=full","pubTime":"2026-04-04 11:35","pubTimestamp":1775273728,"startTime":"0","endTime":"0","summary":"图解创新药主题ETF","market":"hk","thumbnail":"https://img3.gelonghui.com/a0989-a422cedf-f15d-459f-90fa-e7074c8daf48.jpg?guru_height=2241&guru_width=3280&guru_size=1441563","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/a0989-a422cedf-f15d-459f-90fa-e7074c8daf48.jpg?guru_height=2241&guru_width=3280&guru_size=1441563"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4307632","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_fund_highlight","symbols":["BK1161","06978","LU0307460666.USD","LU1969619763.USD","LU2328871848.SGD","LU1719994722.HKD","LU1770034418.SGD","BK1500","LU0588546209.SGD","LU1251922891.USD","LU1303224171.USD","BK1574","06160","BK1588","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624502586","title":"深度观察｜从“烧钱”走向“赚钱”，2025年中国创新药上市公司收入突破1000亿元，我们离全球“领跑”还差多远?","url":"https://stock-news.laohu8.com/highlight/detail?id=2624502586","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624502586?lang=zh_cn&edition=full","pubTime":"2026-04-03 21:06","pubTimestamp":1775221600,"startTime":"0","endTime":"0","summary":"随着2025年各家上市公司年报密集出炉，中国创新药产业的结构性变革，正式浮出水面。《每日经济新闻》记者不完全统计，百济神州、信达生物、华领医药、诺诚健华、乐普生物、荣昌生物、迈博药业、北海康成等公司扭亏为盈。创新药企终于从“烧钱”走向“赚钱”，与此同时，中国已跃升为全球创新药优质在研管线的核心供给地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604033695191747.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604033695191747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","06978","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624307655","title":"奇正藏药：在研产品小儿热立清颗粒属于中药分类1类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2624307655","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624307655?lang=zh_cn&edition=full","pubTime":"2026-04-03 15:57","pubTimestamp":1775203028,"startTime":"0","endTime":"0","summary":"证券之星消息，奇正藏药(002287)04月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司的产品中有创新药吗？奇正藏药回复：您好，公司在研产品小儿热立清颗粒属于中药分类1类创新药，在研产品正乳贴为原中药第6类新药，谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300029387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159992","BK0188","BK1574","06978","002287","BK0033","BK0028","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624314016","title":"中金：国产创新药产业趋势向好 26年学术领域看点较多","url":"https://stock-news.laohu8.com/highlight/detail?id=2624314016","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624314016?lang=zh_cn&edition=full","pubTime":"2026-04-03 10:41","pubTimestamp":1775184094,"startTime":"0","endTime":"0","summary":"中金主要观点如下：研发效率、临床资源优势禀赋，国产创新BD加速、量价齐升NMPA和医药魔方统计显示，2026Q1国内创新药BD总金额超600亿美元，超过2024全年、接近2025全年水平1/2；且平均首付款和平均交易规模均创历史新高。在MNC的积极推动下，多个中国创新资产有望在2026年步入上市申报阶段；基于对国内企业创新能力的认可，多个早期平台化对外合作交易陆续达成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348783233.USD","LU2778985437.USD","LU0359201612.USD","IE00BPRC5H50.USD","LU0348767384.USD","LU0348825331.USD","01276","LU1961090484.USD","BK1588","09926","LU1720050803.USD","IE00B5MMRT66.SGD","LU0588546209.SGD","LU0348784397.USD","09995","LU1794554557.SGD","LU2328871848.SGD","LU0417516902.SGD","LU0307460666.USD","LU0359202008.SGD","LU0540923850.HKD","LU0634319403.HKD","LU1770034418.SGD","LU2488822045.USD","BK1574","LU0561508036.HKD","IE00B543WZ88.USD","LU0348735423.USD","06978","LU2543165471.USD","BK1161","LU1719994722.HKD","LU1969619763.USD","BK1500","BK1583","LU0417516571.SGD","LU1023057109.AUD","01877","LU2399975544.HKD","06938","LU0359201885.HKD","LU1303224171.USD","159992","BK1515","LU0348766576.USD","LU0417516738.SGD","LU0348827113.USD","BK1191","LU2476274720.SGD","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624963182","title":"6连板！600488，直线涨停！创新药，异动！","url":"https://stock-news.laohu8.com/highlight/detail?id=2624963182","media":"e公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624963182?lang=zh_cn&edition=full","pubTime":"2026-04-03 10:14","pubTimestamp":1775182440,"startTime":"0","endTime":"0","summary":"4月3日，CPO概念、数字货币概念、运输服务、半导体、保险等板块涨幅居前；创新药概念、养殖业、供气供热、商业连锁等板块跌幅居前。　　创新药部分走强，津药药业涨停走出6连板，6天累计涨幅近80%。　　津药药业公告称，公司可能存在市场情绪过热、非理性炒作情况，公司基本面未发生重大变化，随时存在快速下跌的风险。截至4月2日，公司最新市盈率为424.82倍。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/2026-04-03/doc-inhtetzf3800539.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK0239","BK0028","BK1161","BK0102","600488","BK1574","BK0012","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624631507","title":"山西证券：生物医药定位国家支柱产业 创新药持续进入爆发期","url":"https://stock-news.laohu8.com/highlight/detail?id=2624631507","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624631507?lang=zh_cn&edition=full","pubTime":"2026-04-03 10:07","pubTimestamp":1775182063,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，山西证券发布研报称，2026年全国两会期间，生物医药产业成为国家政策重点支持产业。国家已将生物医药上升为新兴支柱产业，国产创新药也迎来持续的爆发阶段。国产创新药已成为生物医药产业核心发展方向，已进入持续爆发期2025年是中国创新药出海爆发式增长的一年，各项数据均创下历史新高。2026开年，中国创新药BD出海已展现出延续2025年的势头。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0276","BK1161","BK4581","XBI","06978","BK0183","BK0028","BK1574","BK4585","159992","002500","161726","BK4588","399441","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624639512","title":"易方达中证创新药产业ETF联接发起式A基金经理变动：增聘肖宛远为基金经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2624639512","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624639512?lang=zh_cn&edition=full","pubTime":"2026-04-03 09:33","pubTimestamp":1775180009,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年4月3日，易方达中证创新药产业ETF联接发起式发布公告，增聘肖宛远为基金经理，任职日期自2026年4月3日起，伍臣东不再担任该基金基金经理，离任日期为2026年4月3日，变更后易方达中证创新药产业ETF联接发起式的基金经理为肖宛远。截止2026年4月2日，易方达中证创新药产业ETF联接发起式净值为1.0278，较上一日上涨0.38%，近一年上涨15.03%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300010708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1161","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624635027","title":"诺思格：药石科技为创新药提供临床前服务，我公司为临床CRO公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2624635027","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624635027?lang=zh_cn&edition=full","pubTime":"2026-04-03 08:36","pubTimestamp":1775176572,"startTime":"0","endTime":"0","summary":"证券之星消息，诺思格04月02日在投资者关系平台上答复投资者关心的问题。投资者提问：1.药石科技在分子砌块、连续流工艺、ADC/TPD关键中间体等领域具备国内独一档的技术壁垒，也是很多创新药公司早期研发和CMC开发的重要合作伙伴。药石科技为创新药提供临床前服务，我公司为临床CRO公司，具体业务情况请详见公司定期报告“管理层讨论与分析”章节，两者方向不同。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300009094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300725","BK0229","06978","BK0216","301333","BK1161","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624635686","title":"中信证券：创新药进入密集数据催化期，建议重点关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2624635686","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624635686?lang=zh_cn&edition=full","pubTime":"2026-04-03 08:08","pubTimestamp":1775174880,"startTime":"0","endTime":"0","summary":"　　2026年以来，中国创新药BD交易金额超预期增长，产业全球竞争力进一步提升；国内市场快速放量，从2025年报来看头部创新药企业在新产品驱动下，创新药收入快速增长，biopharma陆续进入盈利拐点；近期多个国际学术大会将至，众多创新药管线进入密集的数据催化期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-04-03/doc-inhteptm8925055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2495084118.USD","BK1147","LU1580142542.USD","LU2148510915.USD","06030","BK1516","BK1574","BK0276","BK0028","BK0196","LU1328615791.USD","600030","LU1720050803.USD","LU1997245094.SGD","LU1997245177.USD","LU0405327148.USD","BK1161","LU1255011170.USD","159992","BK0183","LU1781817850.SGD","LU1997244956.HKD","LU0405327494.USD","LU1655091616.SGD","BK0012","LU2289578879.USD","LU1064130708.USD","BK0188","BK1521","BK1564","LU1794554557.SGD","06978","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624313635","title":"持续打击医保药品领域违法违规问题；中国首个原创核药获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2624313635","media":"21世纪经济报道","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624313635?lang=zh_cn&edition=full","pubTime":"2026-04-03 08:02","pubTimestamp":1775174556,"startTime":"0","endTime":"0","summary":"政策动向国家医保局持续开展打击医保药品领域违法违规问题专项行动近日国家医保局办公室印发《关于深入开展打击医保药品领域违法违规问题专项行动的通知》，对持续打击倒卖医保“回流药”等违法违规问题进行专门部署。《通知》要求，自2026年4月起，以药品追溯码疑点线索核查为抓手，在全国范围内继续深入开展打击医保药品领域违法违规问题专项行动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604033694126468.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604033694126468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09688","BK1588","ADC","AGIX","LU2488822045.USD","CHAT","603168","BK1574","06978","688520","BK0239","BK4231","BK1161","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624633505","title":"股海导航_2026年4月3日_沪深股市公告与交易提示","url":"https://stock-news.laohu8.com/highlight/detail?id=2624633505","media":"股市直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624633505?lang=zh_cn&edition=full","pubTime":"2026-04-03 07:18","pubTimestamp":1775171880,"startTime":"0","endTime":"0","summary":"　　电光科技公告称，公司股票于2026年3月31日、4月1日及4月2日连续三个交易日收盘价格涨幅偏离值累计达22.49%，属于股票交易异常波动。鉴于上述事项尚存在不确定性，为保证公平信息披露，维护投资者利益，公司股票将于2026年4月3日开市起停牌，预计停牌时间不超过5个交易日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-04-03/doc-inhteimi7299896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624032500","title":"公告精选︱松霖科技：一季度净利润预增100.20%到141.99%；津药药业：目前研发以仿制药为主，无在研创新药项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2624032500","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624032500?lang=zh_cn&edition=full","pubTime":"2026-04-02 23:11","pubTimestamp":1775142703,"startTime":"0","endTime":"0","summary":"宁波远洋：拟定增募资不超10.95亿元","market":"sh","thumbnail":"https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4290411","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["159992","603992","06978","600488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624577141","title":"悦康药业最新公告：创新药YKYY018雾化吸入剂获人偏肺病毒治疗与预防临床试验批准全球范围内尚未有获批上市的相关药物和疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2624577141","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624577141?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:50","pubTimestamp":1775123412,"startTime":"0","endTime":"0","summary":"悦康药业公告称，公司全资子公司悦康科创近日获得国家药品监督管理局关于同意YKYY018雾化吸入剂用于人偏肺病毒治疗与预防的两份《药物临床试验批准通知书》。截至目前，全球范围内尚未有获批上市的人偏肺病毒感染治疗药物和疫苗，临床治疗和预防领域存在显著且迫切的未被满足需求。该产品近日也已获得FDA核准签发的关于YKYY018雾化吸入剂用于预防和治疗人偏肺病毒感染进行临床试验的函告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200032595.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","688658","BK0239","06978","159992","BK1161","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624158577","title":"2连板北大医药：公司不存在创新药业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2624158577","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624158577?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:40","pubTimestamp":1775122840,"startTime":"0","endTime":"0","summary":"北大医药(000788.SZ)发布异动公告，经核查，截止本公告披露日，公司不存在创新药业务，主要从事化学药品制剂（仿制药制剂）的研发、生产和销售，主要产品涵盖“抗感染类、镇痛类、精神类、慢病类”等领域。截止本公告披露日，公司第二大股东北大医疗管理有限责任公司尚处于此前已披露的减持计划实施阶段，其减持期间为2026年2月11日至2026年5月10日。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200032325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","06978","BK0028","BK0012","BK0102","BK0122","BK0096","BK0239","BK1161","BK0060","000788","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624574202","title":"润都股份最新公告：1类创新药注册进度变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2624574202","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624574202?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:02","pubTimestamp":1775120546,"startTime":"0","endTime":"0","summary":"润都股份(002923.SZ)公告称，公司从国家药监局获悉，其申报的1类创新药盐酸去甲乌药碱注射液已获批准上市。但经查询，该药品注册申请状态变更为“送受理和举报中心制证”，表示已报送制证，公司尚未取得正式药品注册证书。待取得证书后，公司将及时披露相关信息。敬请投资者注意投资风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200028247.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK0239","BK1574","BK1161","06978","002923"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624245574","title":"汇宇制药：主要创新药研发管线尚处于临床研究阶段具有较大不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2624245574","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624245574?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:01","pubTimestamp":1775120488,"startTime":"0","endTime":"0","summary":"汇宇制药(688553.SH)发布股票交易异常波动公告称，经自查，公司主要创新药研发管线尚处于临床研究阶段，未来还需经历临床研究、新药上市申请等研发阶段，具有较大不确定性；不排除创新药研发过程中还可能会面临研发失败、研发进度不及预期、行业环境变化、市场竞争加剧等诸多潜在风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200028237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","688553","06978","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":0.0112},{"period":"1month","weight":0.1574},{"period":"3month","weight":-0.049},{"period":"6month","weight":-0.379},{"period":"1year","weight":-0.3166},{"period":"ytd","weight":-0.0717}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0253},{"period":"3month","weight":-0.0464},{"period":"6month","weight":-0.0746},{"period":"1year","weight":0.0825},{"period":"ytd","weight":-0.0201}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074078},{"month":2,"riseRate":0.666667,"avgChangeRate":0.181642},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.080929},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.063174},{"month":5,"riseRate":0.4,"avgChangeRate":-0.038349},{"month":6,"riseRate":0.8,"avgChangeRate":0.080731},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000149},{"month":8,"riseRate":0.5,"avgChangeRate":0.012587},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}